A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

Inside the Reproductive Sciences Lab at the University of Colorado Anschutz Medical Campus in Aurora, researchers are on the ...

In 2022, more than 13,000 people died from ovarian cancer, according to the CDC. A common blood test for ovarian cancer is ...

A standard diagnostic test for ovarian cancer is less effective in detecting the disease among Black and Native American ...

She believed that had she had a CA125 blood test earlier - CA125 is a protein in the blood and can be raised in women with ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian cancer.

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

It is essential to rule out the risk of cancer in case of long persisting ovarian cysts, added Dr Sampada Dessai.

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...